Neurology
FDA signals support for development of psychedelic therapies in mental healthmental health
April 28, 2026Neurology, mental health
The US Food and Drug Administration (FDA) has announced a series of measures aimed at supporting the development of psychedelic-based …
Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals
February 17, 2026Manufacturing and Production Gedeon Richter UK, Neurology
Gedeon Richter UK has announced its acquisition of full marketing and distribution rights to Reagila (cariprazine), a schizophrenia treatment, from …
HonorHealth Research Institute announces first patient dosed with new stroke treatment
February 2, 2026Research and Development HonorHealth Research Institute, Neurology, ischemic stroke
HonorHealth Research Institute, a research institution collaborating with a wide range of experts to produce new treatments and devices, has …
Five Facts about spinal muscular atrophy
January 28, 2026Medical Communications Five Facts, Neurology, early diagnosis, five types, gene therapy, muscle weakness, spinal muscular atrophy
1 Spinal muscular atrophy (SMA) is a genetic disease involving the loss of motor neurons in the spinal cord.1 Its …
Spike in searches relating to spinal muscular atrophy following Jesy Nelson disclosure
January 19, 2026Medical Education Neurology, spinal muscular atrophy
New research from the Centre for Surgery has shown a significant rise in Google searches relating to spinal muscular atrophy …
Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy
January 19, 2026Research and Development Biogen, Neurology, Spinraza, spinal muscular atrophy
Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose regimen for the treatment of …
Teva’s Ajovy significantly reduces migraine in children and adolescents
January 12, 2026Research and Development Neurology, Teva, ajovy, migraine
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children and adolescents with episodic migraine …
EpilepsyGTx raises $33m for focal refractory epilepsy gene therapy
December 10, 2025Research and Development EpilepsyGTx, Neurology, epilepsy
EpilepsyGTx, a biotechnology company researching and developing gene therapies for the treatment of refractory epilepsy, has announced $33m raised in …
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
December 8, 2025Research and Development Neurology, UCB, epilepsy
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can significantly reduce the frequency of …
Teva announces positive results from trial of AJOVY for migraine
December 5, 2025Research and Development Neurology, Teva, migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its treatment for chronic (CM) and …
Rare and severe epilepsies – current treatments and advance therapeutics
August 29, 2025Medical Communications, Research and Development Neurology, UCB, epilepsy, epilepsy treatment, rare epilepsies
The current forms of immunotherapy, how T cell therapy works and what the future holds
Epilepsy Research Institute opens 2025-26 grant round with new awards
August 21, 2025Medical Communications, Research and Development Neurology, epilepsy, funding programme, medical research
The Epilepsy Research Institute has opened its 2025-26 Grant Round, offering a wide range of funding opportunities designed to support …
Five Facts about epilepsy
August 21, 2025Medical Communications Five Facts, Neurology, epilepsy, neurological condition, seizures
1 Epilepsy occurs when the normal electrical activity in the brain changes. For many, the cause is unclear, but genes …
FDA decision on Neurizon’s ALS therapy delayed until October
August 18, 2025Medical Communications Coya Therapeutics, Neurizon, Neurology, US Food and Drug Administration, amyotrophic lateral sclerosis
Neurizon Therapeutics has announced that the US Food and Drug Administration (FDA) will delay its decision on the company’s Clinical …
PhotoPharmics expands Parkinson’s Trial into further US states
August 14, 2025Research and Development Neurology, PhotoPharmics, clinical trial, neurodegenerative disorders
US-based PhotoPharmics, has expanded enrollment in its Light for PD clinical trial beyond its original 300 participants, opening new sites …
Latest content
